EU Warns of Schizophrenia Drug Shortage
The European Medicines Agency reported a shortage of injectable schizophrenia treatments across several member states due to manufacturing problems at Pharmathen. Health officials advise professionals to consider alternative medications as supply monitoring continues.
The European Medicines Agency flagged a supply shortage of an injectable schizophrenia treatment across multiple member states on Thursday afternoon, driven by manufacturing disruptions in Greece. The disruption impacts paliperidone palmitate injections distributed by nine pharmaceutical marketers. Healthcare providers face potential treatment continuity hurdles as regulators report no confirmed resolution timeline.
